Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Takeda Pharmaceutical Co ( (JP:4502) ) has provided an announcement.
Takeda’s board has proposed CEO-elect Julie Kim as a new internal director ahead of the June 24, 2026 shareholders meeting, with plans to appoint her representative director, president and CEO immediately after her expected election. Incumbent CEO Christophe Weber will retire from both his executive role and the board on the same day, marking a major leadership transition at the Japanese drugmaker.
The company is also reshaping its board, nominating three new external directors—HP Inc. interim CEO Bruce Broussard, geopolitical adviser Koichiro Kimura and former Johnson & Johnson R&D chief Paul Stoffels—while six long-serving external directors will step down. The board expects the new mix of governance, global healthcare, geopolitical and R&D expertise to support a well-governed CEO transition and underpin Takeda’s long-term growth strategy.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen6116.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co., headquartered in Osaka and Cambridge, is a global biopharmaceutical company focused on developing and commercializing innovative medicines. The company operates across key therapeutic areas including oncology, gastroenterology, neuroscience and rare diseases, with a strong emphasis on research-driven growth and international markets.
Average Trading Volume: 5,119,433
Technical Sentiment Signal: Buy
Current Market Cap: Yen9225.8B
See more data about 4502 stock on TipRanks’ Stock Analysis page.